We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was down 6.44% at $0.63. The stock fell short of the S&P 500, which registered a gain of 0.21% for the day. Meanwhile, the Dow experienced a rise of 1.03%, and the technology-dominated Nasdaq saw a decrease of 0.22%.
The stock of company has fallen by 15.62% in the past month, lagging the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. The company's upcoming EPS is projected at -$0.1, signifying a 58.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1.39 million, up 363.33% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.34 per share and a revenue of $8.03 million, indicating changes of -30.77% and +293.77%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 92, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was down 6.44% at $0.63. The stock fell short of the S&P 500, which registered a gain of 0.21% for the day. Meanwhile, the Dow experienced a rise of 1.03%, and the technology-dominated Nasdaq saw a decrease of 0.22%.
The stock of company has fallen by 15.62% in the past month, lagging the Medical sector's loss of 0.43% and the S&P 500's gain of 1.7%.
The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. The company's upcoming EPS is projected at -$0.1, signifying a 58.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $1.39 million, up 363.33% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.34 per share and a revenue of $8.03 million, indicating changes of -30.77% and +293.77%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Humacyte, Inc. presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 92, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.